Journal article
Engineered amphiphilic peptides enable delivery of proteins and CRISPR-associated nucleases to airway epithelia
Nature communications, Vol.10(1), 4906
10/28/2019
DOI: 10.1038/s41467-019-12922-y
PMCID: PMC6817825
PMID: 31659165
Abstract
The delivery of biologic cargoes to airway epithelial cells is challenging due to the formidable barriers imposed by its specialized and differentiated cells. Among cargoes, recombinant proteins offer therapeutic promise but the lack of effective delivery methods limits their development. Here, we achieve protein and SpCas9 or AsCas12a ribonucleoprotein (RNP) delivery to cultured human well-differentiated airway epithelial cells and mouse lungs with engineered amphiphilic peptides. These shuttle peptides, non-covalently combined with GFP protein or CRISPR-associated nuclease (Cas) RNP, allow rapid entry into cultured human ciliated and non-ciliated epithelial cells and mouse airway epithelia. Instillation of shuttle peptides combined with SpCas9 or AsCas12a RNP achieves editing of loxP sites in airway epithelia of ROSA
mice. We observe no evidence of short-term toxicity with a widespread distribution restricted to the respiratory tract. This peptide-based technology advances potential therapeutic avenues for protein and Cas RNP delivery to refractory airway epithelial cells.
Details
- Title: Subtitle
- Engineered amphiphilic peptides enable delivery of proteins and CRISPR-associated nucleases to airway epithelia
- Creators
- Sateesh Krishnamurthy - University of IowaChristine Wohlford-Lenane - University of IowaSuhas Kandimalla - University of IowaGilles Sartre - University of IowaDavid K Meyerholz - University of IowaVanessa Théberge - Feldan Therapeutics, Québec, QC, Canada.Stéphanie Hallée - Feldan Therapeutics, Québec, QC, Canada.Anne-Marie Duperré - Feldan Therapeutics, Québec, QC, CanadaThomas Del'Guidice - Feldan Therapeutics, Québec, QC, CanadaJean-Pascal Lepetit-Stoffaes - Feldan Therapeutics, Québec, QC, CanadaXavier Barbeau - Feldan Therapeutics, Québec, QC, Canada.David Guay - Feldan Therapeutics, Québec, QC, Canada.Paul B McCray Jr - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Nature communications, Vol.10(1), 4906
- DOI
- 10.1038/s41467-019-12922-y
- PMID
- 31659165
- PMCID
- PMC6817825
- NLM abbreviation
- Nat Commun
- ISSN
- 2041-1723
- eISSN
- 2041-1723
- Grant note
- P30 ES005605 / NIEHS NIH HHS P01 HL091842 / NHLBI NIH HHS P01 HL051670 / NHLBI NIH HHS UG3 HL147366 / NHLBI NIH HHS P30 DK054759 / NIDDK NIH HHS
- Language
- English
- Date published
- 10/28/2019
- Academic Unit
- Microbiology and Immunology; Pulmonary Medicine; Stead Family Department of Pediatrics; Pathology; Internal Medicine
- Record Identifier
- 9984186775002771
Metrics
19 Record Views